Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug 2;16(8):1923-1936.
doi: 10.1080/21645515.2019.1708668. Epub 2020 Jan 29.

Indirect costs of adult pneumococcal disease and the productivity-based rate of return to the 13-valent pneumococcal conjugate vaccine for adults in Turkey

J P Sevilla  1 , Andrew Stawasz  1 , Daria Burnes  1 , Anubhav Agarwal  1 , Basak Hacibedel  2 , Kerem Helvacioglu  2 , Reiko Sato  3 , David E Bloom  1
Affiliations

Indirect costs of adult pneumococcal disease and the productivity-based rate of return to the 13-valent pneumococcal conjugate vaccine for adults in Turkey

J P Sevilla et al. Hum Vaccin Immunother. .

Abstract

Productivity benefits of health technologies are ignored in typical economic evaluations from a health payer's perspective, risking undervaluation. We conduct a productivity-based cost-benefit analysis from a societal perspective and estimate indirect costs of adult pneumococcal disease, vaccination benefits from the adult 13-valent pneumococcal conjugate vaccine (PCV13 Adult), and rates of return to PCV13 Adult for a range of hypothetical vaccination costs. Our context is Turkey's funding PCV13 for the elderly and for non-elderly adults with select comorbidities within the Ministry of Health's National Immunization Program. We use a Markov model with one-year cycles. Indirect costs from death or disability equal the expected present discounted value of lifetime losses in the infected individual's paid and unpaid work and in caregivers' paid work. Vaccination benefits comprise averted indirect costs. Rates of return equal vaccination benefits divided by vaccination costs, minus one. Input parameters are from public data sources. We model comorbidities' effects by scalar multiplication of the parameters of the general population. Indirect costs per treatment episode of inpatient community-acquired pneumonia (CAP), bacteremia, and meningitis - but not for outpatient CAP - approach or exceed Turkish per capita gross domestic product. Vaccination benefits equal $207.02 per vaccination in 2017 US dollars. The rate of return is positive for all hypothetical costs below this. Results are sensitive to herd effects from pediatric vaccination and vaccine efficacy rates. For a wide range of hypothetical vaccination costs, the rate of return compares favorably with those of other global development interventions with well-established strong investment cases.

Keywords: PCV13 Adult; Turkey; cost-benefit analysis; economic evaluation; indirect costs; social rate of return; vaccines.

PubMed Disclaimer

Conflict of interest statement

This study was led by Data for Decisions, LLC (DfD) and sponsored by Pfizer. JP Sevilla and D. Burnes are employees of DfD. A. Stawasz and A. Agarwal were employees of DfD. D. Bloom is a paid consultant to DfD. R. Sato, B. Hacibedel, and K. Helvacıoğlu are employees of Pfizer Inc. The sponsor had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Figures

Figure 1.
Figure 1.
Markov model diagram. Abbreviations: B = bacteremia; ICAP = inpatient community-acquired pneumonia; M = meningitis; MD = moderate disability; OCAP = outpatient community-acquired pneumonia; PCV13 Adult = 13-valent pneumococcal conjugate vaccine for adults; PD = pneumococcal disease; PVS = persistent vegetative state; SD = severe disability; TD = temporary disability
Figure 2.
Figure 2.
Benefits of PCV13 Adult by age at vaccination, assuming herd effects from pediatric vaccination. The solid curve shows vaccine benefits in our base case scenario, which assumes age-varying baseline vaccine efficacies. The dashed curve shows vaccine benefits in our scenario analysis that replaces our base case vaccine efficacies with age-invariant baseline vaccine efficacies
Figure 3.
Figure 3.
Rate of return to the entire Turkish PCV13 Adult program by vaccination cost, assuming herd effects from pediatric vaccination. The solid curve shows rates of return in our base case scenario, which assumes age-varying baseline vaccine efficacies. The dashed curve shows rates of return in our scenario analysis that replaces our base case vaccine efficacies with age-invariant baseline vaccine efficacies
Figure 4.
Figure 4.
Average vaccination benefits by incidence rate ratio over the entire Turkish PCV13 Adult program. The solid curve shows vaccine benefits in our base case scenario, which assumes age-varying baseline vaccine efficacies. The dashed curve shows vaccine benefits in our scenario analysis that replaces our base case vaccine efficacies with age-invariant baseline vaccine efficacies
See this image and copyright information in PMC

References

    1. Plotkin SL, Plotkin SA.. A short history of vaccination. In: Plotkin SA, Orenstein WA, editors. Vaccines. 4th ed. Philadelphia (PA): W.B. Saunders Company; 2004. p. 1–15.
    1. Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG, editors. Cost-effectiveness in health and medicine. 2nd ed. New York (NY): Oxford University Press; 2017.
    1. Bleichrodt H, Quiggin J.. Life-cycle preferences over consumption and health: when is cost-effectiveness analysis equivalent to cost-benefit analysis? J Health Econ. 1999;18:681–708. - PubMed
    1. Hammitt J. Admissible utility functions for health, longevity, and wealth: integrating monetary and life-year measures. J Risk Uncertain. 2013;47:311–25.
    1. Brouwer WB, Koopmanschap MA, Rutten FF. Productivity costs in cost-effectiveness analysis: numerator or denominator: a further discussion. Health Econ. 1997;6:511–14. - PubMed

Publication types